Follow us on Twitter
This page is updated frequently with new Peritoneal-related patent applications. Subscribe to the Peritoneal RSS feed to automatically get the update: related Peritoneal RSS feeds. RSS updates for this page: Peritoneal RSS
Hernia repair device with core and advanced pre-peritoneal disk deployment
Peritoneal dialysis systems and methods that regenerate dialysate
|| List of recent Peritoneal-related patents
|Laparoscopic trocar with ventriculoperitoneal shunt entry port|
An example laparoscopic trocar assembly can be used for insertion of a ventriculoperitoneal (“vp”) shunt into an abdomen and comprises an optical system a trocar sleeve to allow a surgeon to see abdominal tissue being punctured and see into an abdominal cavity. An example trocar assembly comprises an entry port in the trocar's side and a stylet to insert a vp shunt tube into an abdomen.
|Hernia repair device with core and advanced pre-peritoneal disk deployment|
An implant to repair a hole in a muscle wall includes a flat mesh with a central resilient core which deforms to place the core in a hole in a muscle wall and then resiliently expands when released to urge against the perimeter of the hole, dynamically “riding” in the hole as the hole perimeter expands and contracts. Straps on the mesh are tunneled through tissue in the muscle wall containing the hole to hold the mesh with core in place..
|Peritoneal dialysis systems and methods that regenerate dialysate|
A method for providing a peritoneal dialysis treatment that regenerates therapy fluid includes coupling a single fluid circuit having a cleaning cartridge to a peritoneal cavity of a patient, feeding a first amount of therapy fluid into the single fluid circuit, circulating the first amount of therapy fluid multiple times through the single fluid circuit and the peritoneal cavity of the patient, removing a therapeutically effective amount of solutes and ultrafiltrate from the patient using the first amount of therapy fluid, cleaning the first amount of therapy fluid using the cleaning cartridge, removing an amount of fluid from the single fluid circuit, the amount of fluid including at least most of the removed solutes, and feeding a second amount of therapy fluid into the single fluid circuit, the second amount of therapy fluid being approximately equal to the amount of fluid removed from the fluid circuit.. .
A model for practicing transabdominal pre-peritoneal (tapp) and total extraperitoneal (tep) approaches for laparoscopic hernia repairs is provided. The model simulates an insufflated space between the abdominal muscles and peritoneum.
|Intrauterine fetal growth restriction - the biochemical rationale of treatment modalities including extraperitoneal transamniotic fetal supplements|
Intrauterine fetal growth restriction (iugr) is an affliction of a disparaging spectrum, placental insufficiency being the major inciting pathology. The resultant fetal hypoglycemia is alleviated by intravenous hypertonic d-glucose 25-50% maternal supplements, by improving the vmax of placental transfer for d-glucose, in accordance with michaelis-menten model of substrate transfer.
|Medical treatment system and methods using a plurality of fluid lines|
A medical treatment system, such as peritoneal dialysis system, may include control and other features to enhance patient comfort and ease of use. For example, a peritoneal dialysis system may include patient line state detector for detecting whether a patient line is primed before it is to be connected to the patient.
|Isoxazole compound for the treatment of cancer|
The use of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von hippel-lindau syndrome, multicentric castleman disease and/or psioriasis.. .
|System and method for performing alternative and sequential blood and peritoneal dialysis modalities|
A dialysis system includes: a dialysis fluid pump receptacle actuated by a dialysis fluid pump actuator; a dialysis fluid line; a blood filter in fluid communication with the dialysis fluid pump receptacle via the dialysis fluid line; an extracorporeal circuit; a blood pump receptacle actuated by a blood pump actuator and in fluid communication with the blood filter via the extracorporeal circuit; and a control unit that (i) in a first treatment pumps peritoneal dialysis fluid through the dialysis fluid pump receptacle, the dialysis fluid line, the blood filter, the extracorporeal circuit and the blood pump receptacle to the patient's peritoneum operating the dialysis fluid pump actuator and the blood pump actuator at a first pressure, and (ii) in a second treatment pumps blood through the extracorporeal circuit, the blood pump receptacle and the blood filter operating the blood pump actuator at a second, different pressure.. .
|System and method for remote peritoneal dialysis exchanges|
A system and method is provided to allow multiple patients to receive peritoneal dialysis treatment at a walk-in facility without having to keep fresh dialysis solution on hand themselves. The walk-in facility is enabled to receive a peritoneal dialysis prescription from a patient, verify the prescription, determine the appropriate treatment for the patient, provide the patient with the appropriate dialysis solution in the appropriate amount, and enable the patient to undergo a dialysis treatment at the facility.
|System and method for peritoneal dialysis exchanges having reusable fill and drain containers|
A peritoneal dialysis system includes (i) a reusable fill container; (ii) a reusable drain container; and (iii) a reusable continuous ambulatory peritoneal dialysis (“capd”) set configured and arranged to be fluidly connected to at least one of the reusable fill container or the reusable drain container.. .
|System and method for peritoneal dialysis exchanges having reusable energizing unit|
A peritoneal dialysis system includes (i) a fill container, and (ii) an energizing unit that removably accepts the fill container, the energizing unit including a sterilization source so configured and arranged relative to the fill container when accepted by the energizing unit to place fluid within the fill container in a physiologically safe condition for delivery to the peritoneal cavity of a patient.. .
|Universal portable artificial kidney for hemodialysis and peritoneal dialysis|
Methods, systems, and kits are provided for performing hemodialysis, hemodiafiltration, and peritoneal dialysis on a portable machine suitable for both clinical and home use. Peritoneal dialysate can be flowed into and out of the peritoneal cavity, and can also be regenerated within the system, without the need for introducing fresh dialysate.
|Novel compounds as rearranged during transfection (ret) inhibitors|
This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. .
|Universal portable machine for online hemodiafiltration using regenerated dialysate|
Manifolds suitable for use in hemodialysis, hemofiltration, hemodiafiltration, and peritoneal dialysis are provided. One or more of the manifolds can include a manifold body and an external tube.
|Methods and apparatus for revision of obesity procedures|
Methods and apparatus for the endoluminal revision of previously performed obesity procedures which have failed are described. One or more endoluminal instruments may be advanced per-orally into the previously formed failed pouch where a number of different procedures can be performed.
|Method and device for regulating fluid pump pressures|
A method is provided for regulating fluid pump pressures by detecting an elevation differential between a fluid flow control device and the distal end of a fluid line in communication with the fluid flow control device. A fluid flow control device, for instance a peritoneal dialysis device, is at a first height, a distal end of a fluid line is at a second height, and a valved outlet, when open, affords communication between the fluid flow control device and the distal end of the fluid line.
The invention relates to a multiple emulsion for the application of at least one pharmaceutical or cosmetic active ingredient which has an external water phase w1, an oil phase o dispersed in the external water phase w1 and an internal water phase w2 dispersed in the oil phase o, where, in the internal water phase w2, at least one electrolyte selected from the group of the alkali metal and alkaline earth metal halides and sulphates and at least one hydrophilic active ingredient is provided. In order to achieve a high stability of the emulsion, the invention envisages that the external water phase comprises a hydrophilic emulsifier which is a polymer of ethylene oxide and propylene oxide, and that the oil phase o is formed by triacylglycerides and has a lipophilic emulsifier from the group of dimethicones.
|Compositions and methods for treating cancer|
The present invention relates to compositions and methods for treating cancer. In particular, the present invention relates to epcam-targeted immunotoxins and uses thereof in treating peritoneal cancers expressing epcam (e.g., colorectal, ovarian, and pancreatic cancer)..
|Modulation of hsp47 expression|
Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (sina), short interfering rna (sirna), double-stranded rna (dsrna), micro-rna (mirna) or short hairpin rna (shrna)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47.
|Cancer vaccines and vaccination methods|
Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines..
|Body cavity drainage device and methods for using the same|
The present invention provides a drainage tube and method that removes fluid from a peritoneal, abdominal, or other body site. The tube has a central internal passageway for the flow of fluids.
|Peritoneal dialysis system|
The invention also relates to a system using this method.. .
|Apparatus relating to hemodialysis, hemodiafiltration, hemofiltration or peritoneal dialysis having function for rise temperature|
Disclosed is an apparatus having a heating function for hemodialysis, hemodiafiltration, hemofiltration or peritoneal dialysis, wherein the apparatus includes at least one of pipe for transferring at least one fluid of blood and dialsate, and a heating unit for heating at least one fluid of blood and dialsate, wherein the fluids to be heated by the heating unit are substances to be injected into human body; and the heating unit is arranged for measuring flow rates of the fluids to be heated, and injecting temperatures related with the flow rate to heat the fluids to be heated. The heating unit comprises: flow passages through which the fluids to be heated are flowed; a heater formed as a part of the flow passages, for generating heat; and a cover means including a first connection portion through which the fluids enter the flow passages, and a second connection portion through which the fluids come out from the flow passages.
|Novel flavonol compounds, compositions thereof and method for treating bone disorders|
Flavonol compounds, pharmaceutical compositions of the compounds and methods for treating bone disorders by administering the pharmaceutical composition by oral, intravenous, subcutaneous, intra-peritoneal or intramuscular route.. .
|Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers|
In one embodiment, the invention provides a new design of nanocarrier compositions that release their therapeutic load specifically at intraperitoneal cancers' site. These nanocarriers are administered intraperitoneally and comprise a plurality of porous nanoparticulates that (a) are loaded with one or more pharmaceutically-active agents alone or in combination with imaging agents thus providing a theranostic value and (b) that are encapsulated by and that support a lipid bilayer which is disrupted upon contact with a reactive oxygen species generated within the environment of the cancer.
|Tissue repair implant|
Described herein are tissue repair implants comprising at least a first layer of peritoneal membrane. The first layer of peritoneal membrane can be located adjacent to a second layer of peritoneal membrane and can be in direct contact with the second layer of peritoneal membrane.
|System for performing peritoneal dialysis|
The system being characterized by the fact that said liquid distribution system (2) comprises two distinct hub chambers (7,8), the first hub chamber (7) including at least one liquid supply port with dedicated valve means (9), one patient port with dedicated valve means (10) and one pump inlet (26), the second hub chamber (8) including at least, one patient port (18) or warmer port (16) with dedicated valve means and one pump outlet (27), said system furthermore comprising control means arranged to close said patient port (10) of the first hub chamber (7) when said liquid supply port (9) is open and vice versa.. .
|Peritoneal dialysis systems and related devices and methods|
A peritoneal dialysis system includes a base peritoneal dialysis system and a peritoneal dialysis fluid exchange system that operates independently of the base system. The base system includes a first cassette including a first patient line configured to be connected to a patient, and a pd cycler.
|Automated dialysis system using piston and negative pressure|
A peritoneal dialysis system is provided that includes a hardware unit, a disposable unit received by the hardware unit, and a controller. The hardware unit includes a recessed area, a piston having a contact surface, a pneumatic source for supplying a negative pressure, and an actuator configured to move the contact surface of the piston into and out of at least a portion of the recessed area.
|Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases|
Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.. .
|Method for inhibiting peritoneal metastasis caused by gastric cancer cells|
The present invention provides a method for inhibiting peritoneal metastasis caused by gastric cancer cells in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of a connective tissue growth factor (ctgf), wherein the ctgf binds to an integrin α3β1 of the gastric cancer cells. The present invention also provides a method for predicting peritoneal metastasis caused by gastric cancer cells in a subject comprising providing a peritoneal tissue from the subject; measuring a first expression amount of a connective tissue growth factor (ctgf) from the peritoneal tissue; and comparing the first expression amount to a reference expression amount of the ctgf from a non-peritoneal metastasis gastric cancer tissue..
|Fluid for peritoneal dialysis|
The present invention has an object to provide a fluid for peritoneal dialysis with satisfactory body fluid removability, high biocompatibility, and improved storage stability, and the object is attained by a fluid for peritoneal dialysis containing one or more saccharides selected from cyclonigerosylnigerose, cyclomaltosylmaltose, and l-ascorbic acid 2-glucoside.. .
|Method for treating peritoneal fibrosis|
The present invention provides a method for treating, preventing or reducing peritoneal fibrosis comprising administering to a subject in need thereof a pharmacologically effective dose of a type i cannabinoid receptor (cb1r) antagonist or a type ii cannabinoid receptor (cb2r) agonist. Also provided is a dialysis fluid for treating, preventing or reducing peritoneal fibrosis comprising electrolytes, an osmotic agent, a physiologically acceptable ph solution, and a pharmacologically effective dose of a cb1r antagonist or a cb2r agonist..
|Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue|
The present invention relates to a carbohydrate-based peritoneal dialysis fluid, containing a compound selected from the group consisting of glutamine, preferably l-glutamine; a dipeptide capable of releasing glutamine, l-glutamine in free form, preferably selected from the group consisting of glutaminyl-glycine, glycinyl-glutamine, glutaminyl-alanine, alanyl-glutamine; an oligopeptide consisting of two to seven glutamine, preferably l-glutamine residues; and mixtures thereof. The peritoneal dialysis fluids of the present invention are useful for inhibition of technical failure in a person undergoing peritoneal dialysis treatment..
|Substrate having an electron donating surface with metal particles comprising palladium on said surface|
There is disclosed a substrate with an electron donating surface, characterized in having metal particles on said surface, said metal particles comprising palladium and at least one metal selected from the group consisting of gold, ruthenium, rhodium, osmium, iridium, and platinum, wherein the amount of said metal particles is from about 0.001 to about 8 μg/cm2. Examples of coated objects include contact lenses, pacemakers, pacemaker electrodes, stents, dental implants, rupture nets, rupture mesh, blood centrifuge equipment, surgical instruments, gloves, blood bags, artificial heart valves, central venous catheters, peripheral venous catheters, vascular ports, haemodialysis equipment, peritoneal dialysis equipment, plasmapheresis devices, inhalation drug delivery devices, vascular grafts, arterial grafts, cardiac assist devices, wound dressings, intermittent catheters, ecg electrodes, peripheral stents, bone replacing implants, orthopaedic implants, orthopaedic devices, tissue replacing implants, intraocular lenses, sutures, needles, drug delivery devices, endotracheal tubes, shunts, drains, suction devices, hearing aid devices, urethral medical devices, and artificial blood vessels..
|Method and apparatus for peritoneal hypothermia and/or resuscitation|
Embodiments of the invention provide apparatus, systems and methods for introducing fluids into a body cavity for hypothermic, resuscitative, or other treatment. One embodiment provides an apparatus for introducing fluids into a peritoneal cavity comprising an access device for insertion into subcutaneous tissue, an infusion member and an advancement member.
|Use of cyclohexanehexol derivatives in the treatment of ocular diseases|
The present invention relates to methods of treating ocular diseases in a subject by administering to the subject a therapeutically effective amount of one or more cyclohexanehexyl derivatives, or salts thereof, or a medicament comprising a cyclohexanehexol derivative and a pharmaceutically acceptable carrier. More specifically, the invention provides a medicament comprising at least one cyclohexanehexyl derivative of formula (iii) or (iv) useful in preventing or treating ocular diseases, by modulating the folding, oligomerization or aggregation of amyloid β in ocular cells.
Popular terms: [SEARCH]
Peritoneal topics: Peritoneal, Peritoneal Dialysis, Peritoneal Cavity, Dialysis System, Intraperitoneal, Abdominal Cavity, Hemodialysis, Anastomosis, Wireless Communication Device, Colorectal, Hydrogen Sulfide, Sulfonamide, Ultraviolet, Ultraviolet Light, Subcutaneous
Follow us on Twitter
This listing is a sample listing of patent applications related to Peritoneal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Peritoneal with additional patents listed. Browse our RSS directory or Search for other possible listings.